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Background: Cetux]mab (C225) is a chimenzed monodonal antibody that 
targets the epidermal growth factor receptor (EGFR). NSCLC commonly 
espresses the EGFR. which is associated with aggressive tumor behavior and 
poor clinical outcome. Proclinical model systems demons/i-ate radiosonslt]za 
tion following molecular inhibition of EGFR signaling An ongoing Phase II tnal 
is testing catLDdmab, with CRT. in unresectable stage III NSCLC 
Methods: Eligibility criteria include Zubrod performance status (PS) ~<1. weight 
loss ~<5% over past 3 months. FEVl ~>1 2 I. adequate hematologic, hepatic. 
and renal hJnchon. PTS start an initial dose of C225 (400 mglm ~) on day 1 of 
week 1. then weekly doses of C22,5 (250 mg/m ~) until completion of therapy 
(weeks 2 17) Dudng week 2. patients receive CRT (63 Gy/3,5 fractions) with 
weekly earboplatin (C) ALIC 2 and paclitaxel (P) 45 mg/m ~ x 6 doses followed 
by C (AUC 6) and P (200 m~'m ~) x 2 cycles (weeks 12-17). Interim monltonng 
for severe (grade ~>3) or escosslve non hematologieal tox]cities will occur after 
PTS have been t]-eated and followed for at least 90 days after RT. Endpoints 
include safety and compliance of concurrent C225 and CRT. 
Results: 41 PTS have been entered to date with t~ic~ty data available on 22. 
PTS characteristics (n = 33): 67% male. meclan age 68 years (range 42-84). 
48% PS 0.48% stage IliA Data on adverse events related to/Tea/men/(n 22): 
1 PTS with grade 3 thrompocytopenia. ,5PTS with grade 3 Ioukopenia and 1 
PTS with grade 4 leukopenia Number of grade 3 non~ematological toxicitiea: 
MetabolicJlaboratory (4). fatigue (2). pulmonary (2). dermatologic (1). anorexia 
(1). pain (1). and allergy (1) There have been no grade 4 nen~ematologic 
toxicities 
Conclusions: Patient accrual is ongoing This regimen appears to be wall 
tolerated. Updated t~ i~ies  will be reported. 
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Background: The disappointing results of surgical therapy in patients wtth 
locally advanced non small cell lung cancer (NSCLC) have led to the 
investigation of induction treatments. Of these, phase II thals stucles have 
shown that chemo~'adiotherapy administered before surgery yields a down 
staging wtth a s~gnihcant complete pathological response amount. These 
results are often linked to enhanced surgical tox]cities and Impact on survival 
is net clear. 
The aim of this study was to assess the efficacy and morbicity of a novel 
chemo-radiotherapy regimen ~llowed by surgery in patients with locally 
advanced NSCLC 
Ms/hods: From October 2000 to October 2004. 92 patients (age: 34-76 
y. median 59 y: PS (~1) with locally advanced NSCLC (12 liB. 22 IliA. 
47 IIIB. 11 IV) wore proposed induc~on chemo-raciethorapy Chemotherapy 
consisted of 3 cycles of clsplatin 80-100mglm 2 + ifosfamide 3-4.5 glm 2 + 
vinorolbine 25 mg/m 2 (3x) and was administrated on days 1-2-6-15 (1 s~ cycle). 
29 30 3~43 (2 n~ cycle) and daily from day 5.9 to 04 (3 r~ cycle) Concurrent 
thoracic imadiation (40Gy) was given from day 36 to 64 Three~imensional 
dosimetTy was performed using CT scan and ISIS tTeatment planting 
At the end of the induction /Tea/merit. 37 (initial staging: 9 liB. 12 IliA, 14 
IIIB. 2 ~ of these 92 patients (40%) demonstrated objective clinical down- 
staging, had a good general status and were submitted to surgical resection 
(Iobectomy: 16. pneurnoneotomy:15 left and 6 right). For these 37 patients. 
mean (SD) planning tTeatment volume was 656 (368.) cm 3. V26 and V30 were 
17 (,5) and 14 (,5) %. respec0vely Mean (SD) fra~on of oesophagus and heart 
receiving 40Gy were 49 (18.) and 14 (13) % respectively 
Rssults: Complete pathological response was found in 12/37 patients (32%) 
Median follow-up of these 37 patients was 14 months (3 ,51) and projected 
2 years survival is 66% Main side effects of induction tTeatment included 
grade />3 oesophagitis and febnle neutrepenia in 50 and 12% of the patients. 
respectively. Three patients (all left pneurnonectomies) died post operatively 
from Al:~DS: 2 early after massive haemorT'hage and transhJsion and 1 at day 15 
without bleeding or infection. Otherwise. no infection or bronchopleural fistula 
was noted. 
Conclusions: This preliminary study demonstrates that induction chomother 
apy with cisplatin, ifosfamide, vinorelbine combined with thoracic irradiation can 
convert 40% of inoperable locally advanced NSCLC patients to candidates for 
surgical rese~on Early results promise improvement in survival with high but 
tolerable toxicity 
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Background: To test efficacy era weekly schedule of paclitaxel and carboplafin 
in combination with hyperfractionated/acoelerated ra iotherapy (]-IFX~:~,T) in the 
neoadJovant setting in locally advanced NSCLC. 
Methods: Patients (>17 to <70 years. KPS>70%) ~ stage III NSCLC 
(staging: CT~horasJ'abdomerv'cranium. PET. and meclestinescopy) without 
supradevicular lymph node invoivment wore qualified for the study. Paclitaxel 
100 mglsqrn and carboplatin ALIC 2were administered at day 1.8. 15. and 22 
Ibllowed by HFX RT starting at day 43 (2 x 1.5 Gy/day. 5x/week to 45 Gy) 
slrnultaneous paclltasel (50m~tsqm) and carboplatin (~L,IC 2) at day 44. 51. 
and 58. After complete restaging, resections were planned 4 6 weeks after 
completion of the neoadjuvant herapy 
Results: 120 patients have been/Teated and complete data are available (30 
IliA. 88 IIIB: 2 IV) Grad III and Iv' toxicity occurred in 40 and 4 patients 
~gnificant downstaging, no change, and progressive cJsease was observed 
in 60%. 34%. and 6% of the eases R0 resections could be achieved in 62 
(52%) patients lb (12 b%) patients had postoperative complete remission of 
the primary tumor and 31 (26%) patients complete remission of mediastinal 
nodes. After a meclan follow up of 41 months. 61 relapses have been observed. 
Median survival was 14 months. 5 year overall survival 29%. Median survival 
and 5 year overall survival was 04 months and 56% in complete reseoted 
patients and 9 months 0% in unresected patients (p < 0.0001). 
Conclusions: In conclusion the tested neoadJuvant regimen eshiblts tolerable 
te0(iclty, considerable activity and a promising 5 year survival of 56% for 
complete resected patients in advanced stage III lung cancer 
Induction (I) or consolldstlon (C) chemotherapy with 
docetaxel (D) and gemdtablne (G) plus concomitant 
chemoradlctherapy (CTKRT) with docetaxel and carboplstln (Cb) 
for unresectable stage III non-small cell lung cancer (NSCLC) 
patients (p). Initial report of the randomized phase II tTlal 
SLCG 0008 
P. Ganldo I . R. Rosell 2. A. Amllane 2. A. Ramos I . T. Massuti ~. J. Andreu ~ . 
F. Cardenal 4. A. ~¢nalz 4. M. ,tu'nador ~. V. Alherola 6. 1Hospital Ramon y 
Caje/, Madrid Spain, 2 tCD, Badalona, Spain, 3 Hospital General Aficante, 
Al/cante, Spa/n: '~ICO, Barcelona, Spa/n: ~Hospite/ La FE, Valencia, Spa/n: 
eHosptal Amau Vtlanova, Valencia, Spa/n 
Background: Standard ITeatment for unres@ctable stage III NSCLC p includes 
CT and Y,.F~T but the optimal sequence and the integration of new CT agents 
in the concurrent approach are not well defined yet. 
Methods: P with unresectable stage III NSCLC ~ IK />70 and weight loss 
<5% wore inWally randomrsed to sequential b'eatment (arm A). concurrent 
CT/]RT followed by conselidation CT (arm B) or induction CT followed by 
CT/]T~T (arm C). Based on RTOG 9410 results, arm A was removed and the 
study continues with two concomitant arms ~.  C) All p receive 2 cycles of 
D 40m~tm 2 dl. 6 plus G 1200m~tm dl. 8 as I or C therapy Concomitant 
Izeatment includes D 20 m~m and Cb ~L,IC 2 weekly plus 60 Gy ]~] .  
Results: From May 01 to Dec 04 102 p were included. An interim analysis was 
provided when a half of p were recruited (IN: 70). Preliminary data of these 
p (arm A: 18. arm B: 27. arm C: 26) are available although only results of 
both concomitant arm are presented. All groNos are well matched for baseline 
cisease characteristics Toxicity grade 3 4 by CTC and RTOG criteda (27 p 
arm B 1 28. p arm C) was: esophagi/is 22% (arm B) and 20°/= (arm C): 
neumonWs 3 7% (arm B) and 10% (arm C) Neutrepenia during I or C therapy: 
22% (18. p. arm B) and 7% (28 p. arm C) Trombocytopenia 11% (arm B) 
and 7% (arm C) NeutTopenia dudng concomitant herapy: 3 7% (27 p. arm 
B) and 5% (20 p. arm C) No thrombocytoperta or anemia severe were found 
during CT/TRT ]3",e reduction rate was superior in consolidation (39%) than 
in induction (7%) CT. The preliminary response rate wore 66.7% (arm B. 16 
p analyzed) and 50% (arm C. 20 p analyzed). Nine p (13.6%) withdrawn the 
study due to tc0ciclty and there were two b-eatmont related deaths. 
Conclusions: Concomitant ~T ~ weekly Docotaxel and Carboplatin is 
I~asJble without Increasing tc0ciclty. Non platinum CT can be used as induction 
